AR073665A1 - Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) - Google Patents
Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv)Info
- Publication number
- AR073665A1 AR073665A1 ARP090103664A ARP090103664A AR073665A1 AR 073665 A1 AR073665 A1 AR 073665A1 AR P090103664 A ARP090103664 A AR P090103664A AR P090103664 A ARP090103664 A AR P090103664A AR 073665 A1 AR073665 A1 AR 073665A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- treatment
- positive
- hcv
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La solicitud se refiere a ácidos ribonucleicos de doble cadena (dsARNs) que se dirigen a la expresion del gen de sintetasa de carbamoilfosfato 2, transcarbamilasa de aspartato, y dihidro-orotasa (CAD), y a su uso para el tratamiento de infecciones por virus de ARN de cadenas positivas, tales como el virus de hepatitis C (HCV). Cada dsARN comprende una cadena anti-sentido que tiene una secuencia de nucleotidos que es de menos de 30 nucleotidos de longitud, en general de 19 a 25 nucleotidos de longitud, y que es sustancialmente complementaria para cuando menos una parte del ARNm objetivo de CAD. Se puede emplear una pluralidad de estos dsARNs para proporcionar un beneficio terapéutico. La solicitud también se refiere a una composicion farmacéutica que comprende al dsARN junto con un vehículo farmacéuticamente aceptable, y que incluye una modalidad de suministro, tal como liposomas completamente encapsulados o complejos de lípido. La solicitud incluye además métodos para el tratamiento de las enfermedades provocadas por la infeccion por el virus de ARN de cadenas positivas utilizando las composiciones farmacéuticas: y métodos para inhibir la propagacion de los virus de ARN de cadenas positivas dentro y entre las células.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10015508P | 2008-09-25 | 2008-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073665A1 true AR073665A1 (es) | 2010-11-24 |
Family
ID=42026365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103664A AR073665A1 (es) | 2008-09-25 | 2009-09-23 | Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100183704A1 (es) |
AR (1) | AR073665A1 (es) |
TW (1) | TW201018489A (es) |
WO (1) | WO2010034758A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3812462A1 (en) * | 2014-08-20 | 2021-04-28 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006262490A1 (en) * | 2005-06-22 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Targets for inhibiting HCV replication |
US20080145313A1 (en) * | 2006-08-30 | 2008-06-19 | Genesis Research & Development Corporation Limited | Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders |
-
2009
- 2009-09-18 US US12/562,349 patent/US20100183704A1/en not_active Abandoned
- 2009-09-23 AR ARP090103664A patent/AR073665A1/es unknown
- 2009-09-23 WO PCT/EP2009/062347 patent/WO2010034758A2/en active Application Filing
- 2009-09-24 TW TW098132374A patent/TW201018489A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010034758A3 (en) | 2010-08-26 |
US20100183704A1 (en) | 2010-07-22 |
TW201018489A (en) | 2010-05-16 |
WO2010034758A2 (en) | 2010-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066397A1 (es) | Composiciones de arnds y metodo para el tratamiento de infeciones por el virus de papiloma humano (hpv ) | |
HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
EA201391394A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
CR20220468A (es) | AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B (Divisional 2019-0056) | |
PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
MX2024005652A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
AR090869A1 (es) | COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO | |
PE20210668A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
WO2018183808A9 (en) | Antiviral therapeutic | |
SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
PE20230684A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa | |
CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
WO2015042308A3 (en) | Rna-based hiv inhibitors | |
AR084319A1 (es) | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS | |
PE20120115A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
ES2528010T5 (es) | Métodos para detectar la presencia de patógenos intracelulares | |
AR079649A1 (es) | Composiciones y metodos para inhibir la expresion de genes il-18 | |
WO2007111998A3 (en) | Dsrna compositions and methods for treating hpv infection | |
AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
AR078921A1 (es) | Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10 | |
AR073665A1 (es) | Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) | |
CL2013003466A1 (es) | Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv. | |
AR083453A1 (es) | Composiciones y metodos para la inhibicion de la expresion de los genes rrm2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |